Vyleesi Cost in Ohio 2026: Prices, Insurance, and Cheaper Alternatives

What Does Brand-Name Vyleesi Actually Cost in Ohio?

The manufacturer list price for Vyleesi sits at $1,200 per month in 2026, and Ohio retail pharmacy cash prices track that figure closely. Each carton contains single-dose autoinjectors of bremelanotide 1.75 mg for subcutaneous self-injection. Because the drug is dosed as needed (not daily), actual monthly spend depends on how often a patient uses it.

The FDA-approved labeling caps use at 8 doses in any 30-day window and one dose per 24-hour period. A patient who uses Vyleesi twice a month still faces the same carton price as someone using it eight times, which makes per-dose cost highly variable. At two uses per month, each injection effectively costs $600. At eight uses, it drops to $150 per injection.

Ohio pharmacies do not significantly discount the cash price below list. GoodRx and similar coupon aggregators sometimes show modest discounts at select chains, but savings rarely exceed 10-15% off list. The price gap between brand Vyleesi and compounded bremelanotide (discussed below) is the single biggest cost lever for Ohio patients paying out of pocket.

Bremelanotide is the only FDA-approved on-demand injectable treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The RECONNECT trials (two phase 3 studies, combined N=1,247) demonstrated statistically significant improvements in desire and reductions in distress scores compared to placebo over 24 weeks. That clinical profile shapes coverage decisions across Ohio payers.

Does Ohio Medicaid Cover Vyleesi?

No. Ohio Medicaid does not cover Vyleesi for HSDD as of 2026. The drug is excluded from the Ohio Medicaid preferred drug list. Patients enrolled in Ohio Medicaid managed care plans (such as CareSource, Molina, Buckeye Health Plan, or UnitedHealthcare Community Plan) will find bremelanotide is not a reimbursable benefit.

This exclusion is consistent with most state Medicaid programs nationally. HSDD medications have generally not been classified as medically necessary under Medicaid formulary criteria, which tend to prioritize conditions with established morbidity or mortality endpoints. Ohio Medicaid does cover certain other women's health medications, but Vyleesi is not among them.

For Ohio Medicaid enrollees who want to try bremelanotide, the realistic options are the Palatin savings card (which explicitly excludes government insurance beneficiaries), paying cash at retail price, or exploring compounded bremelanotide through a 503A pharmacy. The compounded route is the most affordable path for uninsured or Medicaid patients in Ohio.

According to Dr. Sheryl Kingsberg, a clinical psychologist at University Hospitals Cleveland Medical Center who served as a principal investigator on the RECONNECT trials, "HSDD is a real medical condition that affects approximately 1 in 10 premenopausal women, and access barriers remain a significant issue even years after FDA approval."

Which Commercial Insurance Plans Cover Vyleesi in Ohio?

Coverage depends entirely on your specific plan and employer. No Ohio-based commercial insurer covers Vyleesi universally across all plan tiers. Some plans from Anthem Blue Cross Blue Shield of Ohio, Medical Mutual, and UnitedHealthcare include Vyleesi on specialty tiers with prior authorization. Others exclude it outright.

Prior authorization criteria typically require documentation that the patient has a formal HSDD diagnosis (not explained by another medical or psychiatric condition, relationship factors, or medication side effects), is premenopausal, and has tried or considered flibanserin (Addyi) first. Some plans require a trial-and-failure of flibanserin before approving Vyleesi.

The prior authorization process in Ohio generally takes 5-14 business days. Denials can be appealed. Your prescriber's office handles the submission, but patients should confirm these details with their plan's pharmacy benefits manager directly. Checking whether Vyleesi sits on a specialty tier versus an excluded list before filling the prescription can prevent an unexpected $1,200 charge at the pharmacy counter.

Patients with high-deductible health plans face the full retail cost until they meet their annual deductible, which can be $3,000-$8,000 for individual coverage. In practical terms, many commercially insured Ohio patients pay close to cash price for the first several months of the year.

How the Palatin Technologies Savings Card Works in Ohio

Palatin Technologies (Vyleesi's manufacturer) offers a copay savings card for commercially insured patients. The card can reduce out-of-pocket costs to as low as $0-$50 per fill, depending on the specific program terms in effect for 2026. There are annual caps on total savings, and the card resets each calendar year.

Key eligibility rules: the patient must have commercial insurance (not Medicare, Medicaid, Tricare, or any other government-funded plan), must be 18 or older, and must have a valid prescription for Vyleesi. Ohio residents can enroll through the manufacturer's website or by calling the number on the savings card.

The savings card does not reduce the drug's price. It subsidizes the patient's copay or coinsurance after insurance adjudication. If your insurance plan excludes Vyleesi entirely, the card does not apply because there is no insurance claim to offset. This distinction matters: the card works on top of insurance, not instead of it.

Patients whose insurance denies Vyleesi but who want to try the brand product at full cash price cannot use the savings card. That $1,200 per month comes entirely out of pocket. For patients in this situation, compounded bremelanotide represents a substantially cheaper alternative.

Is Compounded Bremelanotide Legal in Ohio?

Yes. Ohio permits licensed 503A compounding pharmacies to prepare bremelanotide formulations pursuant to a valid patient-specific prescription. A 503A pharmacy compounds medications individually based on a prescriber's order for a specific patient, as regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounded bremelanotide in Ohio typically costs around $140 per month. That is roughly 88% less than the brand product. The compounded version is generally supplied as a multi-use vial rather than single-dose autoinjectors, which means patients draw up each dose with a syringe. The trade-off is price versus convenience.

Several points matter when choosing a compounding pharmacy in Ohio. The pharmacy should hold a valid Ohio Board of Pharmacy license. It should operate under 503A regulations (patient-specific prescriptions) rather than 503B (outsourcing facility) rules unless it holds both designations. Ask whether the pharmacy performs potency and sterility testing on each batch. Not all compounding pharmacies maintain identical quality standards, and injectable preparations carry higher contamination risk than oral compounds.

Ohio telehealth prescribers can legally write prescriptions for compounded bremelanotide and transmit them to a licensed 503A pharmacy. The entire process, from consultation to delivery, can happen without an in-person visit. Ohio updated its telehealth prescribing regulations to allow ongoing prescriber-patient relationships via synchronous audio-video visits, which covers HSDD consultations.

Cash-Pay Strategies: Getting the Lowest Price in Ohio

For Ohio patients paying out of pocket, the price hierarchy is clear. Compounded bremelanotide at approximately $140 per month is the cheapest option. Brand Vyleesi at $1,200 per month is the most expensive. Between those extremes, a few strategies can narrow the gap.

Pharmacy discount cards (GoodRx, RxSaver, SingleCare) occasionally show brand Vyleesi prices in the $1,000-$1,100 range at select Ohio pharmacies, particularly at Costco, which tends to price specialty drugs below competitors. Savings are modest but worth checking. These discount cards work for uninsured and underinsured patients and have no eligibility restrictions.

Specialty pharmacy mail-order programs may offer slightly lower pricing than brick-and-mortar retail. Some Ohio patients report savings of $50-$100 per fill through mail-order, though this varies by pharmacy.

The Palatin patient assistance program (separate from the copay savings card) may provide free Vyleesi to patients who meet income eligibility criteria. Qualification typically requires household income below 300-400% of the federal poverty level and lack of prescription drug coverage. Application requires documentation of income and insurance status.

The Endocrine Society's clinical practice guidelines recognize that cost is a meaningful barrier to HSDD treatment adherence. When patients discontinue therapy due to price, clinical benefit is lost. A 2019 analysis published in the Journal of Sexual Medicine found that out-of-pocket cost was the primary reason women did not fill or refill HSDD prescriptions.

Vyleesi via Telehealth in Ohio: How It Works

Ohio allows Vyleesi and compounded bremelanotide prescriptions through telehealth. The state does not require an in-person visit before a prescriber can write a prescription for bremelanotide, provided the telehealth encounter meets standard-of-care requirements for HSDD diagnosis.

A typical Ohio telehealth HSDD consultation involves a synchronous video visit (15-30 minutes) with a licensed prescriber. The prescriber takes a sexual health history, screens for exclusionary conditions (depression, medication-related causes, relationship distress), confirms premenopausal status, and evaluates whether bremelanotide is appropriate. Blood pressure measurement is relevant because the FDA label notes transient increases in blood pressure after bremelanotide injection, with mean increases of 6 mmHg systolic and 3 mmHg diastolic observed in the RECONNECT trials.

The prescriber can then send the prescription to a retail pharmacy (for brand Vyleesi) or a compounding pharmacy (for compounded bremelanotide). Ohio does not restrict which pharmacy type can receive a telehealth-generated prescription.

Patients with uncontrolled hypertension (blood pressure consistently above 140/90 mmHg) or cardiovascular disease should discuss risks with their prescriber before starting bremelanotide. The RECONNECT studies excluded women with uncontrolled hypertension, so safety data in that population is limited.

How Vyleesi Compares to Other HSDD Treatments on Cost

Bremelanotide is not the only FDA-approved HSDD treatment. Flibanserin (Addyi) received approval in 2015 as a daily oral pill for premenopausal HSDD. The two drugs differ in mechanism, dosing, and price.

Flibanserin acts on serotonin receptors and requires daily dosing regardless of sexual activity. Its generic became available, and cash prices for generic flibanserin in Ohio range from $30-$80 per month. That makes it substantially cheaper than both brand Vyleesi and compounded bremelanotide.

The trade-off is clinical. Flibanserin requires daily administration, carries a boxed warning about hypotension and syncope when combined with alcohol, and takes 4-8 weeks of daily use before clinical benefit appears. Bremelanotide works on demand (45 minutes before activity), does not interact with alcohol, and shows effect from the first dose. In the RECONNECT trials, bremelanotide 1.75 mg produced a statistically significant 0.6-point increase in desire score on the Female Sexual Function Index compared to placebo [1].

For Ohio patients weighing cost versus convenience, the decision matrix looks like this: generic flibanserin is cheapest but requires daily pills and alcohol abstinence. Compounded bremelanotide offers on-demand dosing at $140 per month. Brand Vyleesi provides on-demand dosing in a convenient autoinjector at $1,200 per month.

"The availability of both an on-demand and a daily option gives clinicians flexibility to match treatment to patient preference and lifestyle," noted the American College of Obstetricians and Gynecologists in their practice advisory on HSDD management.

What to Ask Your Ohio Prescriber Before Starting

Before filling a Vyleesi prescription in Ohio, confirm several things with your prescriber. First, ask whether your insurance formulary includes Vyleesi and at what tier. Second, ask whether a prior authorization has been submitted and approved before you go to the pharmacy. Third, ask whether compounded bremelanotide from a 503A pharmacy is an appropriate alternative for your situation.

Your prescriber should also review contraindications. Per the FDA label, bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. The most common side effects in the RECONNECT trials were nausea (40% vs. 1% placebo), flushing (20% vs. 3%), injection site reactions (13% vs. 8%), and headache (11% vs. 8%) [1]. Nausea was the primary reason for discontinuation in clinical trials, occurring most commonly with initial doses and tending to decrease with subsequent use.

Blood pressure should be measured before prescribing. The FDA recommends against use in patients at high cardiovascular risk. Women with a history of melanocyte-stimulating hormone pathway disorders should discuss this with their prescriber, as bremelanotide is a melanocortin-4 receptor agonist and could theoretically affect skin pigmentation with repeated dosing, though clinically significant darkening was not observed in the 24-week RECONNECT studies.

Ohio patients can self-administer the subcutaneous injection at home after training. The autoinjector (brand) requires minimal instruction. The compounded vial-and-syringe method requires a brief demonstration on drawing up the correct volume, though most patients master the technique within one or two attempts.